Cardiol Therapeutics has successfully enrolled 110 patients in its MAVERIC trial before the scheduled deadline and plans to expand the study to enhance efficacy evaluation of CardiolRx™.

YouTube video by SMITHWEEKLY RESEARCH

Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026. Reported positive Phase II ARCHER data showing CardiolRx™ significantly reduced left ventricular mass in patients with acute myocarditis;

Cardiol Therapeutics has secured over $7 million from warrant exercises, strengthening its financial position as it prepares for a major clinical trial in heart disease treatments.

Cardiol Therapeutics (CRDL) has received proceeds of over USD $7 million from the exercise of outstanding common share purchase warrants, strengthening its balance sheet and extending its cash runway into H1 2028.The funds are expected to support operations through topline data from the pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and to help prepare a potential New Drug Application, subject to favorable trial results and regulatory input. Of 5,712,500 warrants originally issued in October 2025, 425,000 remained unexercised as of September 15, 2026, representing additional potential gross proceeds of USD $573,750. Cardiol has exercised its Acceleration Right, causing all remaining warrants to expire at 4:00 p.m. (Eastern Time) on October 16, 2026 if not exercised.

Cardiol Therapeutics has announced a $150 million preliminary base shelf prospectus, paving the way for future securities offerings and highlighting upcoming milestones.

Cardiol Therapeutics is set to participate in the H.C. Wainwright 28th Annual Global Investment Conference, discussing innovative therapies for heart disease.

Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference at the InterContinental Boston Hotel on August 11, 2026, at 9:00 a.m. EDT. A live webcast will be available via the Investors “Events & Presentations” section on the company’s website.Cardiol is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Lead candidate CardiolRx™ is being evaluated in the Phase III MAVERIC trial for recurrent pericarditis and has Orphan Drug Designation from the U.S. FDA. The completed Phase II ARCHER study assessed CardiolRx™ in acute myocarditis. Cardiol is also developing CRD-38, a subcutaneous formulation targeting inflammatory heart disease, including heart failure.

Reported Tuesday, Jul 14 - 7:29am EDT (TheFly subscription required to read more.)

Cardiol Therapeutics has published encouraging Phase II data for its CardiolRx™ therapy, demonstrating significant potential in reducing recurrent pericarditis symptoms and hospitalization rates.

Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) has published the full results of its Phase II MAvERIC study of CardiolRx™ in recurrent pericarditis in the Journal of the American Heart Association, placing this peer-reviewed evidence behind its pivotal Phase III program on the record. The open-label study enrolled 27 adults with symptomatic recurrent pericarditis at eight U.S. clinical […] The post Cardiol Publishes Phase II MAVERIC Data in the Journal of the American Heart Association appeared first on the deep dive.

Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) has published the full results of its Phase II MAvERIC study of CardiolRx™ in recurrent pericarditis in the Journal of the American Heart Association, placing this peer-reviewed evidence behind its pivotal Phase III program on the record. The open-label study enrolled 27 adults with symptomatic recurrent pericarditis at eight U.S. clinical […]

Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) announced that results from its Phase II MAvERIC study of CardiolRx™ in recurrent pericarditis have been published in the peer-reviewed Journal of the American Heart Association. The study found CardiolRx™ was associated with rapid and sustained reductions in pericarditis pain and inflammation in patients with high baseline disease burden, substantial decreases in pericarditis episodes per year, and a favorable safety and tolerability profile.According to Cardiol, these Phase II findings provided the clinical rationale for MAVERIC, a randomized, double-blind, placebo-controlled pivotal Phase III trial evaluating CardiolRx™ for reducing the risk of pericarditis recurrence. Enrollment in MAVERIC is now approaching completion, supported by strong patient interest and highlighting the unmet need in recurrent pericarditis.

Cardiol Therapeutics will discuss its innovative therapies for heart disease at the B. Riley Securities Summit in Boston on July 16, 2026, showcasing its advancements.

Leede Monetary analyst Douglas Loe maintained a “Speculative Purchase” ranking and $11.00 goal on Cardiol Therapeutics Leede Monetary analyst Douglas Loe maintained a “Speculative Purchase” ranking and $11.00 goal on Cardiol Therapeutics (Cardiol Therapeutics Inventory Quote, Chart, Information, Analysts, Financials TSX:CRDL) in an August 6 replace following the corporate’s launch of headline outcomes from its 109-patient Section II ARCHER trial. The research evaluated CardiolRx, the corporate’s orally-active ultra-pure cannabidiol formulation, in acute myocarditis. Loe famous that last knowledge arrived solely barely later than anticipated, with enrollment for the 12-week trial concluding in late fiscal Q3/24 and readout initially anticipated in Q2/25.

Leede Financial analyst Douglas Loe maintained a “Speculative Buy” rating and $11.00 target on Cardiol Therapeutics Leede Financial analyst Douglas Loe maintained a “Speculative Buy” rating and $11.00 target on Cardiol Therapeutics (Cardiol Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:CRDL) in an August 6 update following the company’s release of headline results from its 109-patient Phase II ARCHER trial. The study evaluated CardiolRx, the company’s orally-active ultra-pure cannabidiol formulation, in acute myocarditis.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) today announced topline results from ARCHER, the Company’s Phase II clinical trial in patients with acute myocarditis.

Cardiol Therapeutics (NASDAQ:CRDL) used a presentation at TD Cowen’s 46th Annual Healthcare Conference to outline its clinical development programs targeting inflammation in cardiac disease, with its most advanced asset, CardiolRx, currently being studied in a Phase III trial for recurrent pericardi

Leede Financial analyst Douglas Loe maintained a “Speculative Buy” rating and $11.00 target on Cardiol Therapeutics Leede Financial analyst Douglas Loe maintained a “Speculative Buy” rating and $11.00 target on Cardiol Therapeutics (Cardiol Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:CRDL) in an August 6 update following the company’s release of headline results from its 109-patient Phase II ARCHER trial. The study evaluated CardiolRx, the company’s orally-active ultra-pure cannabidiol formulation, in acute myocarditis.